Anuh Pharma Limited
2,760words
5turns
0analyst exchanges
0executives
Key numbers — 39 extracted
rs,
15.66%
6.52%
24.99%
0.01%
18.32%
0.04%
Rs. 776
42%
34%
28%
31%
Guidance — 5 items
Financial Performance review
opening
“For the year For the Quarter Revenue (FY26) (Cr) 776 (+15.66%) EBIDTA (Excl.”
Financial Performance review
opening
“Other Items) (FY26) (Cr) 67.84 (+6.52%) Total Production (MT) 1733 (+24.99%) Revenue Q4 (Cr) 201 (0.01%) EBIDTA (Excl.”
Financial Performance review
opening
“Other Items) FY26 Q4 (Cr) 23.56 (18.32%) Total Production (MT) 426 (-0.04%) 5 Message from Joint MD Revenue Growth FY26 revenue increased by 15.66% to Rs.”
Gratitude
opening
“The expansion project with state of the art manufacturing facility targeted at regulated market is completed and commercial production from the said new facility started w.e.f.”
Market leadership
opening
“Servicing Society for better tomorrow Donated to Chhatrapati Shikshan Mandal for Building of Toilet Block for about 3200 student of the School Donated to Churchgate Lions Service Funds for Promoting Sports for specially challenged children's Donated to Indian Development Foundation (Project Aashayein) for education to the underprivileged children 37 CSR ….”
Risks & concerns — 3 flagged
We continue to prioritize process innovations, cost Optimization Strategic Market Diversification focusing on export to reduce currency risk.
— The path ahead
He has been a Director several large listed Corporations in India and has had major contribution as Chairman / Member of Audit Committee, Risk Management, Nomination & Remuneration, ESG/CSR, etc.
— Market leadership
We continue to prioritize process innovations, cost Optimization Strategic Market Diversification focusing on export to reduce currency risk.
— Market leadership
Speaking time
1
1
1
1
1
Opening remarks
Financial Performance review
For the year For the Quarter Revenue (FY26) (Cr) 776 (+15.66%) EBIDTA (Excl. Other Items) (FY26) (Cr) 67.84 (+6.52%) Total Production (MT) 1733 (+24.99%) Revenue Q4 (Cr) 201 (0.01%) EBIDTA (Excl. Other Items) FY26 Q4 (Cr) 23.56 (18.32%) Total Production (MT) 426 (-0.04%) 5 Message from Joint MD Revenue Growth FY26 revenue increased by 15.66% to Rs. 776 Cr., supported by strong volume growth and expansion in regulated markets. Profitability The company maintained healthy profitability through operational efficiencies and an improved product mix despite global market challenges during Q4. Manufacturing Excellence Achieved record production volumes with consistently high plant utilization, reflecting strong operational discipline and execution capabilities. Research & Development Continued focus on process innovation, cost optimization, and development of high-value niche APIs to strengthen long-term competitiveness. Regulatory Excellence Successfully completed USFDA and EU GMP inspection
The path ahead
As we look forward, the fundamental drivers of Anuh Pharma Ltd. remain stronger than ever. The extensive volume expansions across our API lines, coupled with high-value regulatory market growth, have placed us in an well- positioned for sustainable long-term growth. We continue to prioritize process innovations, cost Optimization Strategic Market Diversification focusing on export to reduce currency risk.
Strategic Outlook
Our continued investments in compliance, operational efficiency, and capacity enhancement are creating a strong foundation for long-term sustainable growth. With increasing opportunities in regulated markets, a diversified product portfolio, and improving operational leverage, we remain confident in our ability to deliver consistent value to all stakeholders over the coming years.
Gratitude
We want to express my deepest gratitude to all our talented employees for their relentless commitment, and to our shareholders, bankers, clients, and partners for their unwavering faith in our journey. Together, we are crafting a highly sustainable, robust, and valuable pharmaceutical enterprise. Warm regards, Ritesh Shah (Joint MD) Vivek Shah (Joint MD) 7 Financial performance highlights (last 5 years) Total Revenue (INR in Cr.) 659 671 776 492 537 EBITDA (INR in Cr.) 87 52 57 70 66 21-22 22-23 23-24 24-25 25-26 21-22 22-23 23-24 24-25 25-26 PBT (INR in Cr.) PAT (INR in Cr.) 39 31 47 36 78 60 61 47 54 47 21-22 22-23 23-24 24-25 25-26 8 Business mix revenue contribution Revenue Split (Rs. In Cr.) Top 5 customers contribution 417 297 355 365 42% 34% 28% 31% 31% 31% Domestic Export FY 26 FY 25 FY 26 Export Sales Domestic Sales FY 25 Total Sales GEOGRAPHICAL EXPORT SALES FY 2026 GEOGRAPHICAL EXPORT SALES FY 2025 LATIN AMERICA 3% EUROPE 24% AFRICA 33% NORTH AMERICA 5% ASIA 35% LATIN AMERIC
Market leadership
Erythromycin salts Pyrazinamide Sulfadoxine Ambroxol HCL Gliclazide Clobetasol Propionate Betamethasone Dipropionate Competitive Advantage • Regulatory approvals • Environmental health and Safety Compliance (Audited an approved by Multinational companies). • Well diversified sourcing with backward integration in key products. • Surplus capacity available • Financially strong • Strong R&D capabilities 18 Product List Higher Macrolides 1. Azithromycin Anti Asthamatics 1. Acebrophylline Anti Histamine Bilsatin Macrolides 1. 2. 3. 4. 5. 6. 7. Erythromycin 11,12 Carbonate Erythromycin Base Erythromycin Estolate Erythromycin Propionate Erythromycin Ethyl Succinate Erythromycin Phosphate Erythromycin Stearate Expectorant Anti TB Anti Diabetic Anti Malarial 1.Ambroxol HCL 2.Acefylline Piperazine 1. Pyrazinamide Isoniazid 2. 1. Gliclazide 2. Vildagliptin 3. Dapagliflozin 1. Sulfadoxine 2. Pyrimethamine 3. Amodiquine Quinolones 1.Moxifloxacin Anti Bacterial Antibiotic Anti Gout 1. Chloramphenico